X-ELIO, a global leader in the renewable energy sector, and the Net Zero Consortium for Buyers (NZCB) have announced the signing of six virtual power purchase agreements (PPAs) for a combined total ...
Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...
The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...
February 2024 saw Cisco sign a 15-year vPPA to offtake from a 37MW solar farm in Spain developed by IGNIS. The farm is set to ...
Six PPAs to achieve NZCB's sustainability goals Cisco Systems, Biogen, IDEXX Laboratories, and Waters Corporation have signed multiple PPAs with X-ELIO, further reinforcing their commitment to ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
Highlights,Truist Financial Corp adjusted its holdings in Biogen Inc., reducing its stake during the fourth quarter.,Multiple institutional investors modified their positions, contributing to overall ...
Biogen receives exclusive rights to commercialize ... Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback